Journal Article

Hematologic Disorders Associated with Hepatitis C Virus Infection and Their Management

Douglas T. Dieterich and Jerry L. Spivak

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 37, issue 4, pages 533-541
Published in print August 2003 | ISSN: 1058-4838
Published online August 2003 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/376971
Hematologic Disorders Associated with Hepatitis C Virus Infection and Their Management

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

More than 4 million people in the United States are infected with hepatitis C virus (HCV). During the next 20–30 years, the burden of HCV-related mortality and morbidity will likely double. To date, the most effective treatment for chronic HCV infection is the combination of either interferon (IFN)–α or pegylated IFN-α and ribavirin. For a sustained virologic response, treatment adherence and dose maintenance are essential. However, both IFN-α and ribavirin induce hematologic toxicity, such as anemia, neutropenia, and thrombocytopenia, which can compromise treatment adherence and dose maintenance and could, therefore, potentially influence outcomes. Although there are currently no approved treatments for hematologic complications of HCV therapy, studies have shown that hematopoietic growth factors can provide significant benefits. This review highlights the pharmacology, risks, and benefits of recombinant hematopoietic growth factor therapy in HCV-infected patients.

Journal Article.  6527 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.